Company Profile
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company develops products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis.
Its portfolio also includes EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis, and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. Incorporated in 2011 and headquartered in Victoria, Canada, Eupraxia Pharmaceuticals was formerly known as Plaza Capital Partners Inc. before rebranding in May 2012.